<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03995550</url>
  </required_header>
  <id_info>
    <org_study_id>LP0184-1415</org_study_id>
    <secondary_id>2018-004470-10</secondary_id>
    <nct_id>NCT03995550</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single and Multiple Doses of LEO 142397 in Healthy People, Including Japanese</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LEO 142397 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the first clinical trial with LEO 142397. The purpose of the trial is to assess the
      safety and tolerability of LEO 142397, along with the pharmacokinetics (what the body does to
      the drug) and the pharmacodynamics (what the drug does to the body) in healthy people.

      The trial consists of 2 parts:

        -  In Part 1, participants will receive a single dose of LEO 142397. There will be up to 8
           different dose groups.

        -  In Part 2, participants will receive a daily dose of LEO 142397 for 14 days. There will
           be up to 6 different dose groups.

      Each participant will be enrolled into 1 dose group in either Part 1 or Part 2.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Portfolio proritisation
  </why_stopped>
  <start_date type="Anticipated">August 1, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1. Number of treatment-emergent adverse events per subject</measure>
    <time_frame>From Day 1 (postdose) up to Day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1. Having clinically significant abnormalities in systolic blood pressure</measure>
    <time_frame>From Day 1 (postdose) up to Day 8</time_frame>
    <description>Clinical significance (yes/no) of abnormal values as judged by the investigator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1. Having clinically significant abnormalities in diastolic blood pressure</measure>
    <time_frame>From Day 1 (postdose) up to Day 8</time_frame>
    <description>Clinical significance (yes/no) of abnormal values as judged by the investigator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1. Having clinically significant abnormalities in heart rate</measure>
    <time_frame>From Day 1 (postdose) up to Day 8</time_frame>
    <description>Clinical significance (yes/no) of abnormal values as judged by the investigator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1. Having clinically significant abnormalities in oral body temperature</measure>
    <time_frame>From Day 1 (postdose) up to Day 8</time_frame>
    <description>Clinical significance (yes/no) of abnormal values as judged by the investigator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1. Having an abnormal ECG</measure>
    <time_frame>From Day 1 (postdose) up to Day 8</time_frame>
    <description>ECG: electrocardiogram. Abnormal ECG (yes/no) defined as: QT interval corrected for heart rate using Fridericia's formula (QTcF) of &gt;450 msec for males / &gt;470 msec for females, or change from baseline of &gt;30 msec</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2. Number of treatment-emergent adverse events per subject</measure>
    <time_frame>From Day 1 (postdose) up to Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2. Having clinically significant abnormalities in systolic blood pressure</measure>
    <time_frame>From Day 1 (postdose) up to Day 21</time_frame>
    <description>Clinical significance (yes/no) of abnormal values as judged by the investigator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2. Having clinically significant abnormalities in diastolic blood pressure</measure>
    <time_frame>From Day 1 (postdose) up to Day 21</time_frame>
    <description>Clinical significance (yes/no) of abnormal values as judged by the investigator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2. Having clinically significant abnormalities in heart rate</measure>
    <time_frame>From Day 1 (postdose) up to Day 21</time_frame>
    <description>Clinical significance (yes/no) of abnormal values as judged by the investigator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2. Having clinically significant abnormalities in oral body temperature</measure>
    <time_frame>From Day 1 (postdose) up to Day 21</time_frame>
    <description>Clinical significance (yes/no) of abnormal values as judged by the investigator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2. Having an abnormal ECG</measure>
    <time_frame>From Day 1 (postdose) up to Day 21</time_frame>
    <description>ECG: electrocardiogram. Abnormal ECG (yes/no) defined as: QT interval corrected for heart rate using Fridericia's formula (QTcF) of &gt;450 msec for males / &gt;470 msec for females, or maximum change from baseline of &gt;30 msec</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1. AUC0-∞</measure>
    <time_frame>Derived from plasma concentration-time profile from 0-48 hours postdose</time_frame>
    <description>AUC0-∞: area under the plasma concentration-time curve from time zero to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1. Cmax</measure>
    <time_frame>Derived from plasma concentration-time profile from 0-48 hours postdose</time_frame>
    <description>Cmax: maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2. Accumulation ratio</measure>
    <time_frame>Derived from plasma concentration-time profile from 0-24 hours postdose on Day 1 and Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2. AUC0-24</measure>
    <time_frame>Derived from plasma concentration-time profile from 0-24 hours postdose on Day 1 and Day 14</time_frame>
    <description>AUC0-24: area under the plasma concentration-time curve from time zero to 24 hours postdose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2. Cmax</measure>
    <time_frame>Derived from plasma concentration-time profile from 0-24 hours postdose on Day 1 and Day 14</time_frame>
    <description>Cmax: maximum plasma concentration</description>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Single ascending dose Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of LEO 142397 or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single ascending dose Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of LEO 142397 or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single ascending dose Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 single doses, separated by a washout of ≥7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single ascending dose Cohort D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 single doses, separated by a washout of ≥7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single ascending dose Cohort E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of LEO 142397 or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single ascending dose Cohort F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of LEO 142397 or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single ascending dose Cohort G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of LEO 142397 or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single ascending dose Cohort H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of LEO 142397 or placebo - tentative, female-only cohort (to be included only if the number of women recruited in the remaining cohorts is insufficient to assess the pharmacokinetics of LEO 142397 in women). Dose level ≥ that in Cohort C and ≤ that in Cohort D.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple ascending dose Cohort K</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of LEO 142397 or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple ascending dose Cohort L</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of LEO 142397 or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple ascending dose Cohort M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of LEO 142397 or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple ascending dose Cohort N</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of LEO 142397 or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple ascending dose Cohort O</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of LEO 142397 or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple ascending dose Cohort P</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of LEO 142397 or placebo in Japanese-only subjects. Same dose level as for Cohort M.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 142397</intervention_name>
    <description>A compound in development by LEO Pharma A/S</description>
    <arm_group_label>Multiple ascending dose Cohort K</arm_group_label>
    <arm_group_label>Multiple ascending dose Cohort L</arm_group_label>
    <arm_group_label>Multiple ascending dose Cohort M</arm_group_label>
    <arm_group_label>Multiple ascending dose Cohort N</arm_group_label>
    <arm_group_label>Multiple ascending dose Cohort O</arm_group_label>
    <arm_group_label>Multiple ascending dose Cohort P</arm_group_label>
    <arm_group_label>Single ascending dose Cohort A</arm_group_label>
    <arm_group_label>Single ascending dose Cohort B</arm_group_label>
    <arm_group_label>Single ascending dose Cohort C</arm_group_label>
    <arm_group_label>Single ascending dose Cohort D</arm_group_label>
    <arm_group_label>Single ascending dose Cohort E</arm_group_label>
    <arm_group_label>Single ascending dose Cohort F</arm_group_label>
    <arm_group_label>Single ascending dose Cohort G</arm_group_label>
    <arm_group_label>Single ascending dose Cohort H</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Multiple ascending dose Cohort K</arm_group_label>
    <arm_group_label>Multiple ascending dose Cohort L</arm_group_label>
    <arm_group_label>Multiple ascending dose Cohort M</arm_group_label>
    <arm_group_label>Multiple ascending dose Cohort N</arm_group_label>
    <arm_group_label>Multiple ascending dose Cohort O</arm_group_label>
    <arm_group_label>Multiple ascending dose Cohort P</arm_group_label>
    <arm_group_label>Single ascending dose Cohort A</arm_group_label>
    <arm_group_label>Single ascending dose Cohort B</arm_group_label>
    <arm_group_label>Single ascending dose Cohort C</arm_group_label>
    <arm_group_label>Single ascending dose Cohort D</arm_group_label>
    <arm_group_label>Single ascending dose Cohort E</arm_group_label>
    <arm_group_label>Single ascending dose Cohort F</arm_group_label>
    <arm_group_label>Single ascending dose Cohort G</arm_group_label>
    <arm_group_label>Single ascending dose Cohort H</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key inclusion Criteria:

          -  Body mass index of 18.0-32.0 kg/m2, inclusive.

          -  In good health at screening and check-in as judged by the investigator based on
             medical history, physical examination, vital signs assessment, 12-lead
             electrocardiogram, and clinical laboratory evaluations:

               -  Aspartate aminotransferase and alanine aminotransferase values ≤1.5 times the
                  upper limit of normal.

               -  Congenital nonhaemolytic hyperbilirubinaemia (including suspicion of Gilbert's
                  syndrome) is not acceptable.

               -  Haemoglobin value, neutrophil count, and lymphocyte count ≥ the lower limit of
                  normal.

          -  Female subjects of childbearing potential must use a highly effective form of birth
             control, in conjunction with adequate barrier contraception, from randomisation until
             90 days after the follow-up visit.

          -  Male subjects with female partner of childbearing potential must use adequate male
             barrier contraception, in conjunction with a highly effective form of female
             contraception for the partner, from randomisation until 90 days after the follow-up
             visit.

        Key exclusion criteria:

          -  Any surgical or medical condition that might significantly alter the absorption,
             distribution, metabolism, or excretion of any drug.

          -  Any medication, including St. John's wort, known to chronically alter drug absorption
             or elimination processes within 30 days prior to the first dose.

          -  History of any significant infectious disease, as assessed by the investigator, within
             2 weeks prior to the first dose.

          -  Current active tuberculosis based on QuantiFERON-TB Gold test.

          -  Positive hepatitis B surface antigen, hepatitis C virus antibody, or human
             immunodeficiency virus antibodies at screening.

          -  Electrocardiogram abnormalities at screening or check-in.

          -  Smoking of &gt;10 cigarettes per day, on average, within the last 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Expert</last_name>
    <role>Study Director</role>
    <affiliation>LEO Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit Ltd.</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 21, 2019</study_first_submitted>
  <study_first_submitted_qc>June 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2019</study_first_posted>
  <last_update_submitted>August 1, 2019</last_update_submitted>
  <last_update_submitted_qc>August 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data feasibility requests and research proposals are sent to disclosure@leo-pharma.com. If feasibility to share the data from a trial is granted, the ultimate decision is made by an external to the company board (Patient and Scientific Review Board). Data sharing is further subject to signed data sharing agreement. Data will be available in a closed environment for a specified period on time.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>External researchers with no commercial interest who provide scientifically sound research proposal</ipd_access_criteria>
    <ipd_url>http://www.leo-pharma.com/Home/Research-and-Development/Clinical-trial-disclosure/Access-to-patient-level-data.aspx</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

